Tryptase loss-of-function mutations reduce tryptase expression and predict asthmatic response to anti-IgE therapy
D. Choy (South San Francisco, United States of America), N. Trivedi (San Francisco, United States of America), A. Dressen (South San Francisco, United States of America), M. Babina (Berlin, Germany), R. Ahuja (San Francisco, United States of America), T. Yi (South San Francisco, United States of America), J. Jackman (South San Francisco, United States of America), G. Ji (South San Francisco, United States of America), J. Hackney (South San Francisco, United States of America), L. Orozco-Guerra (South San Francisco, United States of America), D. Chang (South San Francisco, United States of America), G. Caughey (San Francisco, United States of America), B. Yaspan (San Francisco, United States of America)
Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD
Session: Novel immunology-based therapies in asthma and COPD
Session type: Oral Presentation
Number: 1652
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Choy (South San Francisco, United States of America), N. Trivedi (San Francisco, United States of America), A. Dressen (South San Francisco, United States of America), M. Babina (Berlin, Germany), R. Ahuja (San Francisco, United States of America), T. Yi (South San Francisco, United States of America), J. Jackman (South San Francisco, United States of America), G. Ji (South San Francisco, United States of America), J. Hackney (South San Francisco, United States of America), L. Orozco-Guerra (South San Francisco, United States of America), D. Chang (South San Francisco, United States of America), G. Caughey (San Francisco, United States of America), B. Yaspan (San Francisco, United States of America). Tryptase loss-of-function mutations reduce tryptase expression and predict asthmatic response to anti-IgE therapy. 1652
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy Source: Eur Respir J, 58 (6) 2003969; 10.1183/13993003.03969-2020 Year: 2021
Do leukotriene antagonists reduce eosinophil numbers in induced sputum from asthmatic patients as a consequence of increased apoptosis induction? Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002
PP115 – COL4A3 degradation predicts anti-IgE response in severe asthma Source: ERS Lung Science Conference 2021 Year: 2021
A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients? Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Aspirin enhances the CD11b expression of eosinophils in patients with aspirin-intolerance asthma Source: Eur Respir J 2003; 22: Suppl. 45, 572s Year: 2003
Sputum gene expression of mast cell tryptase and carboxypeptidase A3 are increased in eosinophilic asthma Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011
Differential expression of mRNA encoding for pro-inflammatory and angiogenic proteins in aspirin-tolerant and -intolerant asthma, following oral provocative aspirin challenge Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status? Source: International Congress 2017 – Monitoring asthma control Year: 2017
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Allergen immunotherapy induces a suppressor memory response that is mediated by IL-10 in a mouse model of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 194s Year: 2003
Recruitment of eosinophils and increased expression of mast cells tryptase in the bronchial mucosa of patients with allergic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 508s Year: 2002
Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
Differential gene expression and cytokine production from neutrophils in asthma phenotypes Source: Eur Respir J 2010; 35: 522-531 Year: 2010
Cytokine production profile of T-lymphocytes and frequence of regulatory T-cells in patients with allergic asthma receiving anti-IgE therapy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
The effect of anti-IL-5 therapy on sputum cells and cytokines in asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Anti-IL-5 antibody reduces the increase of CD34+ eosinophils in a mouse model of airway allergic eosinophilia Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Imiquimod attenuate airway inflammation and decrease the expression of TARC in allergic asthmatic mice Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006